Investing

JPMorgan says there's a new GLP-1 drug player and its shares can rally 80%

Structure Therapeutics could one day boast a competitive obesity product and go up against Eli Lilly and the like, according to JPMorgan.

adminadmin
May 22, 2024 - 00:00
 0  9
JPMorgan says there's a new GLP-1 drug player and its shares can rally 80%
Structure Therapeutics could one day boast a competitive obesity product and go up against Eli Lilly and the like, according to JPMorgan.
Read More

Tags:

Previous Article

Morgan Stanley says shares of this Nvidia supplier could pop if AI leader gives ...

Next Article

JPMorgan strategist stays stubbornly negative on stocks even as other Wall Stree...

admin
admin

Related Posts

Defensive stocks like this top software maker offer sanctuary in times of uncertainty, Wall Street analysts say

Defensive stocks like this top software maker offer san...

admin Aug 18, 2024  0  3

Bernstein tech analyst calls Oracle his top investment idea

Bernstein tech analyst calls Oracle his top investment ...

admin Sep 13, 2024  0  10

Ariel fund manager on a pick to buy post-Fed and this jumping tech stock to stick with

Ariel fund manager on a pick to buy post-Fed and this j...

admin Sep 20, 2024  0  3